<DOC>
	<DOCNO>NCT01914770</DOCNO>
	<brief_summary>This pool analysis ass data Phase 3 belimumab registration study BLISS-52 ( aka BEL110752 ) BLISS-76 ( aka BEL110751 ) . The analysis pre-planned agree prior unblinding either study . The primary objective evaluate impact belimumab treatment severe subpopulation systemic lupus erythematosus ( SLE ) subject BLISS-52 BLISS-76 aid physicians payer decision making . Subjects modify Intent-to-Treat ( ITT ) population define randomized subject receive least 1 dose study agent . This severe subpopulation renal , neurological , haematological , cardiovascular/respiratory organ domain involvement ( defined British Isles Lupus Assessment Group ( BILAG ) domain score A , B C least one domains ) baseline AND anti-double-stranded deoxyribonucleic acid ( anti-dsDNA ) positive ( ≥ 30 IU/mL ) baseline OR low C3 and/or C4 complement relative normal range baseline .</brief_summary>
	<brief_title>Effectiveness Belimumab Treatment Subpopulation Systemic Lupus Erythematosus ( SLE ) Patients : Pooled Analysis BLISS-52 BLISS-76</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Eligible subject BLISS52 BLISS76 include : clinical diagnosis systemic lupus erythematosus ( SLE ) accord American College Rheumatology ( ACR ) criteria `` active '' ( systemic lupus erythematosus ) SLE disease , define safety oestrogen lupus national assessment ( SELENA ) systemic lupus erythematosus disease activity index ( SLEDAI ) disease activity score least 6 screen unequivocally positive antinuclear antibody ( ANA ) test result , 2 independent time point within study screen period 1 positive historical test result 1 positive test result screen period . ANA test result obtain screen period consider positive ANA titer ≥ 1:80 and/or antidsDNA serum antibody ≥ 30 IU/mL stable SLE treatment regimen least 30 day prior Day 0 , consist follow ( alone combination ) : prednisone equivalent ( 0 40 mg/day use combination SLE treatment 7.5 40 mg/day alone ) , antimalarial , nonsteroidal anti inflammatory drug ( NSAIDs ) , immunosuppressive therapy ( i.e. , methotrexate , azathioprine , leflunomide , mycophenolate calcineurin inhibitor , sirolimus , oral cyclophosphamide , 6mercaptopurine , thalidomide ) . Additional inclusion criterion purpose analysis : subpopulation patient pool modified IntenttoTreat population BLISS52 BLISS76 renal , neurological , haematological , cardiovascular/respiratory organ domain involvement ( defined BILAG domain score A , B C least one domains ) baseline 1 following : antidsDNA positive ( ≥ 30 IU/mL ) baseline , OR low C3 and/or C4 complement relative normal range baseline . Key exclusion criterion BLISS52 BLISS76 include : severe active lupus nephritis Central Nervous System ( CNS ) lupus pregnancy receipt B cell target therapy time receipt investigational agent within 60 day prior Day 0 nonbiologics within 1 year biologics receipt abatacept ( within 1 year ) , intravenous ( IV ) cyclophosphamide ( within 6 month ) , antitumor necrosis factor ( antiTNF ) therapy , anakinra , IV immunoglobulin ( IVIG ) , prednisone &gt; 100 mg/day , plasmapheresis within 3 month , live vaccine within 1 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>pool analysis</keyword>
	<keyword>quality life</keyword>
	<keyword>SELENA SLEDAI</keyword>
	<keyword>SLE</keyword>
	<keyword>steroid use</keyword>
	<keyword>responder rate</keyword>
	<keyword>flare</keyword>
	<keyword>belimumab</keyword>
	<keyword>BILAG</keyword>
</DOC>